Category Archives: Global
By Pharm Exec | Published: March 28, 2014
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
By Julian Upton | Published: March 27, 2014
Europe’s biotech industry body, EuropaBio, has launched a report urging European governments to remain committed to biotech research, development and innovation (RDI) incentives, following release of the European Commission’s (EC) 2014 Innovation Scoreboard.
By Guest Blogger | Published: March 25, 2014
By Peter O’ Donnell. So at last it’s happened. Adaptive licensing has leapt from the pages of learned journals into the real world of European regulation. Is this the beginning of the end of binary decision-making on the merits of a new medicine? Has a half-century of the “yes/no” authorization process peaked, to be replaced […]
By Pharm Exec | Published: March 25, 2014
The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
By Pharm Exec | Published: March 21, 2014
European physicians have insufficient knowledge of biosimilars, according to a survey carried out by the Alliance for Safe Biologic Medicines (ASBM). Only 22% of physicians consider themselves “very familiar” with this category of medicines, and while a majority (54%) have a “basic understanding” of biosimilars, 24% of participants could not define or have not heard about […]